Form 4: Nuvalent CFO Sells Shares Under 10b5-1 Plan

Nuvalent's Chief Financial Officer, Alexandra Balcom, sold 1,683 shares of Class A Common Stock for a weighted average price of $85.57 after exercising options, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Alexandra Balcom, Nuvalent's Chief Financial Officer, exercised options to acquire 1,683 shares of Class A Common Stock at $18.93 per share.
• Concurrently, she sold 1,683 shares of Class A Common Stock at a weighted average price of $85.57 per share, with prices ranging from $85.00 to $85.69.
• These transactions were executed on October 15, 2025, under a Rule 10b5-1 trading plan adopted on December 12, 2024.
• Following these transactions, Balcom directly owns 61,734 shares of Class A Common Stock and 28,979 stock options.
• The stock options underlying the transaction vested 25% on January 4, 2023, with the remainder vesting over three years in equal monthly installments, subject to continued service.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan. The transaction is profitable for the insider, and the 10b5-1 plan mitigates concerns about opportunistic selling. However, any insider selling can sometimes be viewed with slight caution by the market, leading to a neutral to slightly positive sentiment.

Positives

• The sale of shares at a weighted average price of $85.57, significantly higher than the exercise price of $18.93, indicates a profitable transaction for the reporting person.
• The transactions were conducted under a Rule 10b5-1 trading plan, suggesting a pre-scheduled and non-discretionary sale, which can be viewed positively as it mitigates concerns about opportunistic insider trading.

Negatives

• The sale of shares by a Chief Financial Officer, even under a 10b5-1 plan, could be interpreted by some investors as a lack of confidence, although the amount is relatively small.

Risks

• Potential for market misinterpretation of insider selling, despite the existence of a 10b5-1 plan, which could lead to negative sentiment if not properly understood.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May observe insider selling, but the execution under a Rule 10b5-1 plan suggests the transaction was pre-scheduled and not based on new, undisclosed negative information. The volume of shares sold is relatively small in the context of the company's overall market capitalization.
• Employees: No direct impact on employees is indicated by this filing, beyond the ongoing vesting schedule for the reporting person's stock options.

Next Steps

• The remaining stock options will continue to vest over the next three years in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

Key Dates

Recommendation

This Form 4 filing details a pre-planned insider transaction by the Chief Financial Officer, involving the exercise of stock options and subsequent sale of a relatively small number of shares. Such routine disclosures, especially those executed under a Rule 10b5-1 plan, typically do not provide sufficient new information to warrant a change in investment recommendation. Investors should consider broader company fundamentals and market conditions rather than solely relying on this specific insider transaction.

Keywords

Nuvalent, NUVL, insider trading, Form 4, stock option exercise, share sale, Alexandra Balcom, Chief Financial Officer, 10b5-1 plan